Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 19 de 19
Filter
1.
Expert Opin Ther Pat ; 28(2): 123-128, 2018 Feb.
Article in English | MEDLINE | ID: mdl-29224409

ABSTRACT

INTRODUCTION: The development of molecular diagnostics is a complex endeavor, with multiple regulatory pathways to consider and numerous approaches to development and commercialization. Companion diagnostics, devices which are "essential for the safe and effective use of a corresponding drug or diagnostic product" (see U.S. Food & Drug Administration, In Vitro Diagnostics - Companion Diagnostics, U.S. Dept. of Health & Human Services(2016), available at https://www.fda.gov/medicaldevices/productsandmedicalprocedures/invitrodiagnostics/ucm407297.htm ) and complementary diagnostics, which are more broadly associated with a class of drug, are becoming increasingly important as integral components of the implementation of precision medicine. Areas covered: The following article will highlight the intellectual property ('IP') considerations pertinent to molecular diagnostics development with special emphasis on companion diagnostics. Expert opinion/commentary Summary: For all molecular diagnostics, intellectual property (IP) concerns are of paramount concern, whether the device will be marketed only in the United States or abroad. Taking steps to protect IP at each stage of product development is critical to optimize profitability of a diagnostic product. Also the legal framework around IP protection of diagnostic technologies has been changing over the previous few years and can be expected to continue to change in the foreseeable near future, thus, a comprehensive IP strategy should take into account the fact that changes in the law can be expected.


Subject(s)
Intellectual Property , Molecular Diagnostic Techniques , Pathology, Molecular/legislation & jurisprudence , Humans , Patents as Topic , Precision Medicine/methods , United States
4.
Expert Rev Mol Diagn ; 15(7): 869-80, 2015.
Article in English | MEDLINE | ID: mdl-26109316

ABSTRACT

Companion diagnostics are essential for the safe and effective use of the corresponding therapeutic products. The US FDA has approved a number of companion diagnostics used to select cancer patients for treatment with contemporaneously approved novel therapeutics. The processes of co-development and co-approval of a therapeutic product and its companion diagnostic have been a learning experience that continues to evolve. Using several companion diagnostics as examples, this article describes the challenges associated with the scientific, clinical and regulatory hurdles faced by FDA and industry alike. Taken together, this discussion is intended to assist manufacturers toward a successful companion diagnostics development plan.


Subject(s)
Molecular Diagnostic Techniques , Pathology, Molecular/methods , Device Approval , Diagnostic Test Approval , Humans , Pathology, Molecular/legislation & jurisprudence , United States , United States Food and Drug Administration
8.
Cancer J ; 20(1): 85-90, 2014.
Article in English | MEDLINE | ID: mdl-24445770

ABSTRACT

Legal and regulatory issues have assumed heightened importance in molecular pathology. Patents on relationships between human gene variants and clinical phenotypes, as well as on the underlying gene sequences themselves, have been extremely controversial. However, recent Supreme Court decisions appear to have rendered invalid these classes of patents. The Clinical Laboratory Improvement Amendments of 1988 have been the primary basis for laboratory oversight in the United States, whereas the Food and Drug Administration has been responsible for regulating in vitro test kits distributed in interstate commerce. However, the Food and Drug Administration has recently announced its intention to regulate laboratory-developed tests, raising concerns in the laboratory community. This article reviews recent developments impacting the legal status of gene patenting and oversight of molecular pathology testing in the United States.


Subject(s)
Intellectual Property , Pathology, Molecular/legislation & jurisprudence , Humans , Patents as Topic , Pathology, Molecular/methods , United States
9.
Genet Med ; 16(7): 504-9, 2014 Jul.
Article in English | MEDLINE | ID: mdl-24357850

ABSTRACT

The Supreme Court's recent decision in Association for Molecular Pathology v. Myriad Genetics portrays the human genome as a product of nature. This frames medical genetics as an extractive industry that mines a natural resource to produce valuable goods and services. Natural resource law offers insights into problems medical geneticists can expect after this decision and suggests possible solutions. Increased competition among clinical laboratories offers various benefits but threatens to increase fragmentation of genetic data resources, potentially causing waste in the form of lost opportunities to discover the clinical significance of particular gene variants. The solution lies in addressing legal barriers to appropriate data sharing. Sustainable discovery in the field of medical genetics can best be achieved through voluntary data sharing rather than command-and-control tactics, but voluntary mechanisms must be conceived broadly to include market-based approaches as well as donative and publicly funded data commons. The recently revised Health Insurance Portability and Accountability Act Privacy Rule offers an improved--but still imperfect--framework for market-oriented data sharing. This article explores strategies for addressing the Privacy Rule's remaining defects. America is close to having a legal framework that can reward innovators, protect privacy, and promote needed data sharing to advance medical genetics.


Subject(s)
Data Mining/legislation & jurisprudence , Genome, Human , Information Dissemination/legislation & jurisprudence , Neoplasms/genetics , Neoplasms/pathology , Pathology, Molecular/legislation & jurisprudence , Confidentiality/legislation & jurisprudence , Health Insurance Portability and Accountability Act , Humans , Pathology, Molecular/ethics , Privacy/legislation & jurisprudence , Supreme Court Decisions , United States
11.
Pathologe ; 34(1): 9-15, 2013 Feb.
Article in German | MEDLINE | ID: mdl-23322303

ABSTRACT

The increase in density of information available in relation to patients and research participants, in particular in the context of genetic diagnostics and analysis, results in an increased potential for uncovering details which were unexpected but are of particular significance for the patient. Deciding how this information is dealt with and who is entitled to receive this information, is a medicolegal and ethical balancing act. Incidental findings and the challenges posed by the advent of personalised medicine are but two areas which increasingly impact medical disciplines that do not conventionally work directly with patients. Both areas raise questions of what is legally required and morally necessary. The authors briefly sketch these two areas and the medicolegal and ethical implications for diagnostics and research in pathology.


Subject(s)
Biomedical Research/ethics , Biomedical Research/legislation & jurisprudence , Confidentiality/ethics , Confidentiality/legislation & jurisprudence , Ethics, Medical , Incidental Findings , Pathology, Molecular/ethics , Pathology, Molecular/legislation & jurisprudence , Pathology/ethics , Pathology/legislation & jurisprudence , Adult , Antineoplastic Agents/toxicity , Child , Education, Medical, Continuing/ethics , Education, Medical, Continuing/legislation & jurisprudence , Female , Genetic Privacy/ethics , Genetic Privacy/legislation & jurisprudence , Genetic Testing/ethics , Genetic Testing/legislation & jurisprudence , Germany , Humans , Male , Malpractice/legislation & jurisprudence , Morals , Patient Advocacy/ethics , Patient Advocacy/legislation & jurisprudence , Patient Education as Topic/ethics , Patient Education as Topic/legislation & jurisprudence , Personal Autonomy , Pharmacogenetics , Precision Medicine/ethics , Risk Assessment , Truth Disclosure/ethics
12.
N Biotechnol ; 29(6): 611-2, 2012 Sep 15.
Article in English | MEDLINE | ID: mdl-22504736

ABSTRACT

This special issue of New Biotechnology is focused on molecular diagnostics and personalised medicine and appears at an epochal moment in the development of the field. The practice of medicine is taking a significant and irrevocable turn towards personalisation, due to the great progress in areas such as genomics, pharmacogenomics and molecular diagnosis. It becomes increasingly apparent that to deliver the promise of personalised treatments, more and more novel medicines discovered today will be presented together with innovative companion diagnostics. The contributions to this volume touch on many disciplines, ranging from cell biology to genetics, immunology, molecular diagnostics, pharmaceutics and economic issues. The contributions of clinicians and basic scientists are synergistically presented to underline better the wide spectrum of studies that can contribute to the new field of personalised medicine. The promising perspectives of individualised treatments are related not only to higher effectiveness, but also to increased efficiency. This is relevant not only for the individual patient, but even more so for the general public, within a wider economical perspective where resources are limited and it becomes more and more mandatory to close the gap between social costs and benefits. This approach follows the steps of a stratified and individualised medicine and finds its final goal in an individualised healthcare.


Subject(s)
Pathology, Molecular , Precision Medicine , Humans , Inventions , Pathology, Molecular/economics , Pathology, Molecular/legislation & jurisprudence , Precision Medicine/economics
15.
Clin. transl. oncol. (Print) ; 13(9): 636-651, sept. 2011. tab, ilus
Article in English | IBECS | ID: ibc-125868

ABSTRACT

The identification of HER2 alterations in advanced gastric carcinomas is of critical importance in daily clinical practice as such neoplasms require specific treatment with trastuzumab. For these reasons, pathologists and oncologists with expertise in gastric carcinomas and HER2 testing from both organisations (SEAP and SEOM) have endeavoured to discuss and agree on national guidelines for HER2 testing in gastric carcinomas. These guidelines are based on the experience of those who participated in the discussions and also on experience published internationally. These agreed guidelines give the minimum requirements that a pathological anatomy laboratory must fulfil in order to guarantee adequate HER2 testing in daily practice. Any laboratories which do not meet the minimum standards set out in the guidelines must make every effort to achieve compliance (AU)


Subject(s)
Humans , Male , Female , Consensus , Genes, erbB-2/genetics , Genetic Testing/methods , Genetic Testing , Practice Guidelines as Topic , Stomach Neoplasms/genetics , Medical Oncology/legislation & jurisprudence , Medical Oncology/methods , Medical Oncology/organization & administration , Pathology, Molecular/legislation & jurisprudence , Pathology, Molecular/methods , Pathology, Molecular/organization & administration , Societies, Medical/legislation & jurisprudence , Stomach Neoplasms/diagnosis , Stomach Neoplasms/pathology , Biomarkers, Tumor/genetics
16.
Clin Transl Oncol ; 13(9): 636-51, 2011 Sep.
Article in English | MEDLINE | ID: mdl-21865135

ABSTRACT

The identification of HER2 alterations in advanced gastric carcinomas is of critical importance in daily clinical practice as such neoplasms require specific treatment with trastuzumab. For these reasons, pathologists and oncologists with expertise in gastric carcinomas and HER2 testing from both organisations (SEAP and SEOM) have endeavoured to discuss and agree on national guidelines for HER2 testing in gastric carcinomas. These guidelines are based on the experience of those who participated in the discussions and also on experience published internationally. These agreed guidelines give the minimum requirements that a pathological anatomy laboratory must fulfil in order to guarantee adequate HER2 testing in daily practice. Any laboratories which do not meet the minimum standards set out in the guidelines must make every effort to achieve compliance.


Subject(s)
Carcinoma/genetics , Consensus , Genes, erbB-2 , Genetic Testing/methods , Genetic Testing/statistics & numerical data , Stomach Neoplasms/genetics , Algorithms , Biomarkers, Tumor/analysis , Biomarkers, Tumor/genetics , Carcinoma/diagnosis , Carcinoma/pathology , Clinical Laboratory Techniques/methods , Clinical Trials as Topic , Genes, erbB-2/genetics , Humans , Medical Oncology/legislation & jurisprudence , Medical Oncology/methods , Medical Oncology/organization & administration , Pathology, Molecular/legislation & jurisprudence , Pathology, Molecular/methods , Pathology, Molecular/organization & administration , Practice Guidelines as Topic , Societies, Medical/legislation & jurisprudence , Spain , Stomach Neoplasms/diagnosis , Stomach Neoplasms/pathology
18.
Trends Biotechnol ; 28(11): 548-51, 2010 Nov.
Article in English | MEDLINE | ID: mdl-20832881

ABSTRACT

The recent decision in the case Association for Molecular Pathology et al. v. United States Patent and Trademark Office et al. shocked the biotechnology industry. Although the case could be overturned on appeal, it will probably change how gene patents are written. The effects of the decision might be most strongly felt in the short term by clinical laboratories that develop new genetic tests based on single genes. However, evidence suggests that patents are less effective as an incentive to innovate in the field of genetic diagnostics than for pharmaceuticals. In addition, as genomic technologies move towards whole-genome analysis, policy arguments for patent protection for single genes become less compelling. It is clear that the intellectual property model challenged by the Myriad decision will have to be replaced if new genetic technologies are to achieve their full potential in promoting 'the progress of science and useful arts'.


Subject(s)
Genetic Techniques/statistics & numerical data , Genetic Techniques/trends , Molecular Diagnostic Techniques/statistics & numerical data , Molecular Diagnostic Techniques/trends , Patents as Topic/legislation & jurisprudence , Pathology, Molecular/legislation & jurisprudence , Pathology, Molecular/methods , Humans , United States
19.
Swiss Med Wkly ; 139(49-50): 712-8, 2009 Dec 12.
Article in English | MEDLINE | ID: mdl-20047134

ABSTRACT

Sudden cardiac death (SCD) is a major cause of premature death in young adults and children in developed countries. Standard forensic autopsy procedures are often unsuccessful in determining the cause of SCD. Post-mortem genetic testing, also called molecular autopsy, has revealed that a non-negligible number of these deaths are a result of inherited cardiac diseases, including arrhythmic disorders such as congenital long QT syndrome and Brugada syndrome. Due to the heritability of these diseases, the potential implications for living relatives must be taken into consideration. Advanced diagnostic analyses, genetic counselling, and interdisciplinary collaboration should be integral parts of clinical and forensic practice. In this article we present a multidisciplinary collaboration established in Lausanne, with the goal of properly informing families of these pathologies and their implications for surviving family members. In Switzerland, as in many other countries, legal guidelines for genetic testing do not address the use of molecular tools for post-mortem genetic analyses in forensic practice. In this article we present the standard practice guidelines established by our multidisciplinary team.


Subject(s)
Death, Sudden, Cardiac/etiology , Forensic Pathology , Interdisciplinary Communication , Arrhythmias, Cardiac/complications , Arrhythmias, Cardiac/genetics , Autopsy , Cause of Death , Death, Sudden, Cardiac/pathology , Forensic Pathology/ethics , Forensic Pathology/legislation & jurisprudence , Forensic Pathology/methods , Genetic Counseling/ethics , Genetic Counseling/legislation & jurisprudence , Genetic Diseases, Inborn/complications , Genetic Diseases, Inborn/genetics , Genetic Predisposition to Disease , Genetic Testing/ethics , Genetic Testing/legislation & jurisprudence , Humans , Molecular Diagnostic Techniques/ethics , Pathology, Molecular/ethics , Pathology, Molecular/legislation & jurisprudence , Practice Guidelines as Topic
SELECTION OF CITATIONS
SEARCH DETAIL
...